CARE AND MANAGEMENT OF PRE-ECLAMPSIA

Contribution of PAPP-A, PIGF and sFlt-1 assays
Pre-eclampsia: background

- Pre-eclampsia (PE) is defined as recent onset hypertension (arterial pressure ≥ 140/90 mmHg for 2 measurements at 4hr interval) and proteinuria (≥ 300 mg/24hr) after 20 weeks amenorrhea (WA) in a priori normotensive women.

- Early onset (between 20 and 34 WA) is associated with a less favourable prognosis with higher fetal and maternal risks.

- PE is a major cause of intrauterine growth retardation, responsible for a third of very premature births in France.

- The incidence of PE in France is respectively from 1 to 3% in nulliparous and 0.5 to 1.5% in multiparous females\(^1\). It is the second most frequent cause of maternal deaths of obstetric origin after postpartum hemorrhage.

- In severe forms (10% of cases), maternal, fetal and/or neonatal complications can develop rapidly with serious complications and a potentially fatal prognosis.

- Induced delivery may be proposed by the clinician based on the clinical signs of the patient and the impact on the fetus.

Every year 24,000 to 40,000 women in France are affected by PE (of a total of 800,000 pregnancies).

Assays of pre-eclampsia biomarkers can be used for:

- **SCREENING in the 1st trimester of pregnancy:** identifying patients at risk of developing pre-eclampsia who could benefit from preventive measures (for example, treatment with 150-160 mg aspirin implemented 16 WA)\(^2\) and/or intensive outpatient monitoring.

- **NEW PREDICTIVE in the 2nd semester of pregnancy:** allows prediction or exclusion of pre-eclampsia several weeks in advance of its onset so that early care can be provided to prevent complications or the patient can be reassured and kept at home.

Screening in 1st trimester (11+0 to 13+6 WA)\(^3-5\)

**Benefits**

- Establish close obstetric monitoring
- Initiate aspirin therapy at low doses before 16 WA

**Risk calculation**

"PE risk" patients can be screened for the presence of risk factors with the Doppler measurement of the pulsatility index (PI) of the uterine arteries (UAD), mean arterial pressure (MAP) and the assay of PAPP-A and PIGF biomarkers.

**Risk factors incorporated in the calculation**

- BMI
- Geographical origin
- Parity
- Personal or family history of PE
- Chronic high blood pressure, treated or not
- Smoking

**Risk calculation**

In 2013, the Nicolaides team (Akolekar et al, 2013) has published a study with 58,884 single pregnancies, 2.4% of which with PE. The detection rate is better for early PEs and, compared to purely clinical information, the combination of biophysical and biochemical data significantly improves the detection rate.

The same team published a new study at the start of 2016 of 35,948 pregnancies (O’Gorman et al, 2016), 2.9% of which with PE, using a new calculation method. The combination of clinical information with PIGF, PAPP-A, UAD and MAP enables screening, with 5% false positives, of 82% of PEs before 32 WA (42% with only maternal risk factors); the detection rate is 59% for PEs between 32+0 and 36+6 WA and 37% between 37+0 and 39+6 WA (34% and 31% respectively with only maternal risk factors).
**Predictive test for 2nd trimester (> 20 WA) [6-8]**

**Benefits**

- Reassure and keep at home patients with a very low short-term risk (80% of patients).
- Early warning for patients who are likely to develop the first signs of PE (headache, visual disturbances, edema, abdominal pains ...).
- Referral of patients with a high short-term risk for early hospitalization or regular monitoring.

The PIGF (Placental Growth Factor), produced by the placenta, is an angiogenic factor that plays a key role in the fetoplacental vascular development.

- The PIGF concentration drops abnormally low 9 to 11 weeks before the occurrence of PE.

The imbalance in sFlt-1 and PIGF concentrations is detectable several weeks before the clinical onset of pre-eclampsia.

The sFlt-1/PIGF ratio has a better positive predictive value (PPV) than the measurement of sFlt-1 by itself.

SFlt-1 (soluble PIGF receptor) is an antiangiogenic factor. It captures the circulating PIGF that cannot be attached to its membrane receptor, thereby decreasing its pro-angiogenic activity.

- The PIGF concentration is abnormally elevated around 5 weeks before the occurrence of PE.
PROGNOSIS study[8]

The PROGNOSIS study is a multicentre, prospective, non-interventional, randomized, double-blind study that evaluated the short-term prediction of pre-eclampsia in pregnant women at risk of pre-eclampsia. Between December 2010 and January 2014, 1270 patients were enrolled and 30 centres located in 14 countries participated. The results were published at the start of 2016.

sFlt-1/PIGF ratio: a decision-making aid for the clinician

A ratio <38 is the basis for referring women to outpatient care with a negative predictive value (NPV) of 99.3% at one week. A ratio ≥ 38 flags the need for care and hospitalization of patients at high risk with a positive predictive value (PPV) of 36.7% at 4 weeks of developing a PE.

In the presence of a warning sign, the sFlt-1/PIGF ratio alerts the clinician to possible development of pre-eclampsia.
Strategy for use of biomarkers

- Patient at risk of PE
  - Risk factors (RFs)

At time of screening of T21:
- IP + MAP + PIGF + PAPP-A + RF
  - PE screening

- Standard monitoring
  - Intensive outpatient monitoring. Preventive measures

CLINICAL PATHOLOGY

SCREENING

11⁺⁰

Patient at risk of PE

Risk factors (RFs)

CLINICAL

13⁺⁶ 20

CLINICAL PATHOLOGY

PREDICTIVE TEST

2nd and 3rd trimesters

Identification of imminent PEs

sFlt-1/PlGF ratio

Predictive at weeks 1–4

- ratio < 38
- ratio ≥ 38

DIAGNOSIS

- Symptoms
- sFlt-1/PIGF ratio

- ratio > 85 (if < 34 WA)
- ratio > 110 (if ≥ 34 WA)

PE diagnosis and prognosis

Management

1. New onset or exacerbated arterial hypertension
2. New onset or exacerbated proteinuria
3. Epigastric pain
4. Excessive edema
5. Headaches
6. Visual disorders

- Sudden weight gain
- Thrombopenia (< 100 giga/L)
- Elevated hepatic enzymes
- IUGR (suspected)
- Abnormal ultrasound result for uterine arteries

Appearance of a 1st warning sign*

NPV 99.3% at week 1

PPV 36.7% at week 4

Outpatient monitoring

Intensive monitoring or hospitalization

* - New onset or exacerbated arterial hypertension
- New onset or exacerbated proteinuria
- Epigastric pain
- Excessive edema
- Headaches
- Visual disorders
In practice

For pre-eclampsia screening in 1st trimester

**Recommendation**
- PIGF and PAPP-A assay

**Sampling**
- Between 11° et 13°6 WA
- Blood sample: use a separate dry tube for PE screening. After removal of clot, centrifuge at high speed to separate serum.

**Storage and transport**
- Refrigerate (+2 °C to +8 °C)

**Document to be enclosed with sample**
- Special information sheet for PE screening in 1st trimester to be downloaded from the online tests guide on www.biomnis.com.
  Biomnis Analysis Code = PECLA

For the pre-eclampsia predictive test

**Recommendation**
- sFlt-1/PIGF assays

**Sampling**
- Starting from 20 WA
- Blood sample (2 ml): use a separate dry tube for PE screening. After removal of clot, centrifuge at high speed to separate the serum.

**Storage and transport**
- Freeze (-18 °C)

**Information to be provided**
- It is essential to provide pregnancy dates (date of pregnancy or crown-rump length and date of ultrasound examination between weeks 11°0 and 13°6) and date of sample

For more information
- All information can be found in the online tests guide on our website www.biomnis.com.
  Biomnis Analysis Code = TPREE

References


Glossary

- UAD: Doppler ultrasound of uterine arteries
- RF: Risk factor
- FP: False positive rate
- MAP: Mean arterial pressure
- PAPP-A: Pregnancy-Associated Plasma Protein-A
- PE: Pre-eclampsia
- PIGF: Placental Growth Factor
- WA: Week of amenorrhea
- sFlt-1: fms-like tyrosine kinase 1 (soluble fraction of type VEGF receptor (VEGF-R1))
- VEGF: Vascular Endothelial Growth Factor
- PPV: Positive predictive value
- NPV: Negative predictive value